Last €0.03 EUR
Change Today +0.011 / 57.89%
Volume 100.0K
YP1 On Other Exchanges
As of 5:55 AM 10/2/14 All times are local (Market data is delayed by at least 15 minutes).

prima biomed ltd (YP1) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/24/14 - €0.05
52 Week Low
10/14/13 - €0.0060
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PRIMA BIOMED LTD (YP1)

Related News

No related news articles were found.

prima biomed ltd (YP1) Related Businessweek News

No Related Businessweek News Found

prima biomed ltd (YP1) Details

Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunocellular therapeutic products for the treatment of cancer. Its lead product is CVac, an autologous dendritic cell-based product currently in clinical trials for ovarian and pancreatic cancer patients. Prima BioMed Ltd. is based in Sydney, Australia.

31 Employees
Last Reported Date: 08/27/14

prima biomed ltd (YP1) Top Compensated Officers

Chief Executive Officer, Chief Financial Offi...
Total Annual Compensation: A$250.2K
Chief Technical Officer
Total Annual Compensation: A$325.6K
General Counsel and Company Secretary
Total Annual Compensation: A$160.0K
Total Annual Compensation: A$364.4K
Compensation as of Fiscal Year 2014.

prima biomed ltd (YP1) Key Developments

Prima Biomed Ltd. Reports Preliminary Audited Consolidated Earnings Results for the Year Ended June 30, 2014

Prima Biomed Ltd. reported preliminary audited consolidated earnings results for the year ended June 30, 2014. For the period, the company reported total other income was AUD 3,140,066 against AUD 4,005,394 a year ago. Loss before income tax expense was AUD 13,329,774 against AUD 15,138,798 a year ago. Loss for the year is attributable to owners of the company was AUD 13,343,381 against AUD 15,225,671 a year ago. Basic and diluted loss per share was 1.09 cents against 1.42 cents a year ago. Net cash outflow from operating activities was AUD 14,227,161 against AUD 16,037,126 a year ago. Payments for plant and equipment were AUD 103,675 against AUD 507,924 a year ago. This decrease was essentially due to lower foreign exchange gains and less interest income being earned during fiscal year 2014 (AUD 406,628 in fiscal year 2014 against AUD 1,417,613 in fiscal year 2013).

Prima Biomed Ltd. Announces Executive Changes

The Board of Prima Biomed Ltd. announced that Marc Voigt has been appointed as Chief Executive Officer of Prima. Mr. Voigt, Prima's Chief Business Officer and Chief Financial Officer as well as General Manager of the company's European Operations, replaces US based Matthew Lehman who will step down from the Board but remain as an adviser to the company to facilitate an orderly transition. Following his appointment as CEO, Marc Voigt will join the Prima Board as an Executive Director. Marc has more than 16 years of experience in the financial and biotech industry, having joined the Prima team in 2011 as the General Manager, European Operations based in Berlin, Germany.

Prima BioMed Ltd Announces CVac Demonstration of Positive Trend in Overall Survival in Second Remission Ovarian Cancer

Prima BioMed Ltd. announced that CVac has demonstrated a positive trend in overall survival (OS) over standard of care in second remission ovarian cancer patients in the CAN-003 protocol. In second remission patients (n=20) from CAN-003, median OS for control group patients was 26.25 months while a median for CVac patients was not yet reached after 30 months (hazard ratio=0.17; p=0.07). Medians for the control group and CVac treated patients have not yet been reached for first remission patients. CAN-003 is a 63-patient phase 2 study evaluating the effects of CVac, as compared to an observational standard of care arm (OSC), in epithelial ovarian cancer patients in complete remission after first or second line treatment. In accordance with the protocol design, the first seven patients on the trial were all assigned to receive CVac in order to test the comparability of product manufacturing in a new facility. The subsequent 56 patients were randomized 1:1 to either the CVac group or observational standard of care (OSC) and included in the intent-to-treat analysis. 36 patients were in first remission (19 patients were assigned to CVac and 17 to OSC) and 20 patients were in second remission (10 patients were each assigned to CVac or OSC). Final PFS data was analysed after thorough quality control reviews of investigator-evaluated progression and appropriate censoring of data from patients who had not progressed during the study. The primary objectives of the trial are to determine the safety of CVac administration and to determine CVac's effect on progression-free survival. Secondary objectives of the trial are to determine CVac's effect of overall survival and to evaluate host immunologic responses to CVac.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
YP1:GR €0.03 EUR +0.011

YP1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for YP1.
View Industry Companies

Industry Analysis


Industry Average

Valuation YP1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.4x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRIMA BIOMED LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at